Publications

Found 97 results
[ Type(Desc)] Year
Conference Paper
KA Glass, AK Ross, SA Compton, CA Gersbach, FT Moutos, BT Estes, and F Guilak. "Anatomically-Shaped Tissue-Engineered Cartilage with Tunable and Inducible Anti-Inflammatory Capabilities." In Tissue Engineering, Part A, S330. Vol. 21. 2015.
N Farhang, JM Brunger, JD Stover, PI Thakore, BD Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPRi Immunomodulation for Tissue Engineering/Stem Cell Therapies Targeting Intervertebral Disc Degeneration." In Tissue Engineering, Part A, S170. Vol. 21. 2015.
J Black, A Adler, H Hutchinson, H Wang, G Pitt, K Leong, and C Gersbach. "Multiplex Gene Activation by CRISPR/Cas9-Based Transcription Factors for the Direct Conversion of Fibroblasts to a Neuronal Phenotype." In Molecular Therapy, S26. Vol. 23. 2015.
E Schulz, T Bergmann, M Gebbing, V Schildgen, O Schildgen, C Gersbach, and A Ehrhardt. "Mutation Detection Following Non-Homologous End Joining (NHEJ): A Comparison of Different Semi Quantitative and Quantitative Methods." In Molecular Therapy, S126-S127. Vol. 22. 2014.
P Perez-Pinera, DG Ousterout, JM Brunger, AM Farin, KA Glass, F Guilak, GE Crawford, AJ Hartemink, and CA Gersbach. "Synergistic and Tunable Gene Activation by Combinations of Synthetic Transcription Factors." In Molecular Therapy, S93. Vol. 21. 2013.
KA Glass, JM Brunger, CA Gersbach, and F Guilak. "TUNABLE EXPRESSION OF IL-1RA IN GENETICALLY MODIFIED MESENCHYMAL STEM CELLS FOR CARTILAGE TISSUE ENGINEERING." In Osteoarthritis and Cartilage, S282-S283. Vol. 21. 2013.
Journal Article
CA Gersbach, and P Perez-Pinera. "Activating human genes with zinc finger proteins, transcription activator-like effectors and CRISPR/Cas9 for gene therapy and regenerative medicine." Expert Opinion on Therapeutic Targets 18, no. 8 (2014): 835-839.
AJ García, RE Guldberg, BA Byers, CA Gersbach, and JE Phillips. "Addressing cell-sourcing limitations with gene therapy." IEEE Engineering in Medicine and Biology Magazine 22, no. 5 (2003): 65-70.
P Perez-Pinera, DG Ousterout, and CA Gersbach. "Advances in targeted genome editing." Current Opinion in Chemical Biology 16, no. 3-4 (2012): 268-277.
FT Moutos, KA Glass, SA Compton, AK Ross, CA Gersbach, F Guilak, and BT Estes. "Anatomically shaped tissue-engineered cartilage with tunable and inducible anticytokine delivery for biological joint resurfacing." Proceedings of the National Academy of Sciences of USA 113, no. 31 (2016): E4513-E4522.
CA Gersbach,, JM Le Doux, and AJ García. "Biomaterial-mediated retroviral gene transfer using self-assembled monolayers." Biomaterials 28, no. 34 (2007): 5121-5127.
CE Nelson, and CA Gersbach. "Cas9 loosens its grip on off-target sites." Nature Biotechnology 34, no. 3 (2016): 298-299.
CA Gersbach, T Gaj, and CF Barbas. "Comparing Genome Editing Technologies." Genetic Engineering and Biotechnology News 34, no. 5 (2014): 1, 32-34.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
DG Ousterout, AM Kabadi, PI Thakore, P Perez-Pinera, MT Brown, WH Majoros, TE Reddy, and CA Gersbach. "Correction of dystrophin expression in cells from Duchenne muscular dystrophy patients through genomic excision of exon 51 by zinc finger nucleases." Molecular Therapy 23, no. 3 (2015): 523-532.
K High, PD Gregory, and C Gersbach. "CRISPR technology for gene therapy." Nature Medicine 20, no. 5 (2014): 476-477.
N Farhang, JM Brunger, JD Stover, PI Thakore, B Lawrence, F Guilak, CA Gersbach, LA Setton, and RD Bowles. "CRISPR-Based Epigenome Editing of Cytokine Receptors for the Promotion of Cell Survival and Tissue Deposition in Inflammatory Environments." Tissue Engineering, Part A 23, no. 15-16 (2017): 738-749.
JM Brunger, A Zutshi, VP Willard, CA Gersbach, and F Guilak. "CRISPR/Cas9 editing of induced pluripotent stem cells for engineering inflammation-resistant tissues." Arthritis and Rheumatology 69, no. 5 (2016): 1111-1121.
TS Klann, JB Black, M Chellappan, A Safi, L Song, IB Hilton, GE Crawford, TE Reddy, and CA Gersbach. "CRISPR-Cas9 epigenome editing enables high-throughput screening for functional regulatory elements in the human genome." Nature Biotechnology 35, no. 6 (2017): 561-568.
S Chakraborty, H Ji, AM Kabadi, CA Gersbach, N Christoforou, and KW Leong. "A CRISPR/Cas9-based system for reprogramming cell lineage specification." Stem Cell Reports 3, no. 6 (2014): 940-947.
PI Thakore, and CA Gersbach. "Design, Assembly, and Characterization of TALE-Based Transcriptional Activators and Repressors." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 71-88.
DG Ousterout, and CA Gersbach. "The Development of TALE Nucleases for Biotechnology." Methods in molecular biology (Clifton, N.J.) 1338 (2016): 27-42.
J Lee, L Xu, TM Gibson, CA Gersbach, and BA Sullenger. "Differential effects of toll-like receptor stimulation on mRNA-driven myogenic conversion of human and mouse fibroblasts." Biochemical and Biophysical Research Communications 478, no. 3 (2016): 1484-1490.
CA Gersbach, T Gaj, RM Gordley, and CF Barbas. "Directed evolution of recombinase specificity by split gene reassembly." Nucleic Acids Research 38, no. 12 (2010): 4198-4206.
PI Thakore, JB Black, IB Hilton, and CA Gersbach. "Editing the epigenome: technologies for programmable transcription and epigenetic modulation." Nature Methods 13, no. 2 (2016): 127-137.

Pages